Literature DB >> 15000421

Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.

Liping Zhang1, Stuart L Beal, Lewis B Sheiner.   

Abstract

Dose [-concentration]-effect relationships can be obtained by fitting a predictive pharmacokinetic (PK)-pharmacodynamic (PD) model to both concentration and effect observations. Either a model can befit simultaneously to all the data ("simultaneous" method), or first a model can befit to the PK data and then a model can be fit to the PD data, conditioning in some way on the PK data or on the estimates of the PK parameters ("sequential" method). Using simulated data, we compare the performance of the simultaneous method with that of three sequential method variants with respect to computation time, estimation precision, and inference. Using NONMEM, under various study designs, observations of one type of PK and one type of PD response from different numbers of individuals were simulated according to a one-compartment PK model and direct Emax PD model, with parameters drawn from an appropriate population distribution. The same PK and PD models were fit to these observations using simultaneous and sequential methods. Performance measures include computation time,fraction of cases for which estimates are successfully obtained, precision of PD parameter estimates, precision of PD parameter standard error estimates, and type-I error rates of a likelihood ratio test. With the sequential method, computation time is less, and estimates are more likely to be obtained. Using the First Order Conditional Estimation (FOCE) method, a sequential approach that conditions on both population PK parameter estimates and PK data, estimates PD parameters and their standard errors about as well as the "gold standard" simultaneous method, and saves about 40% computation time. Type-I error rates of likelihood ratio test for both simultaneous and sequential approaches are close to the nominal rates.

Entities:  

Mesh:

Year:  2003        PMID: 15000421     DOI: 10.1023/b:jopa.0000012998.04442.1f

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  8 in total

1.  Population modelling in drug development.

Authors:  L Sheiner; J Wakefield
Journal:  Stat Methods Med Res       Date:  1999-09       Impact factor: 3.021

2.  Errors-in-variables in joint population pharmacokinetic/pharmacodynamic modeling.

Authors:  J Bennett; J Wakefield
Journal:  Biometrics       Date:  2001-09       Impact factor: 2.571

3.  Developing and testing integrated multicompartment models to describe a single-input multiple-output study using the SAAM II software system.

Authors:  D M Foster
Journal:  Adv Exp Med Biol       Date:  1998       Impact factor: 2.622

4.  Making the most of sparse clinical data by using a predictive-model-based analysis, illustrated with a stavudine pharmacokinetic study.

Authors:  L Zhang; R Price; F Aweeka; S E Bellibas; L B Sheiner
Journal:  Eur J Pharm Sci       Date:  2001-02       Impact factor: 4.384

5.  Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model.

Authors:  H C Kimko; S S Reele; N H Holford; C C Peck
Journal:  Clin Pharmacol Ther       Date:  2000-11       Impact factor: 6.875

6.  Modeling a bivariate control system: LH and testosterone response to the GnRH antagonist antide.

Authors:  K E Fattinger; D Verotta; H C Porchet; A Munafo; J Y Le Cotonnec; L B Sheiner
Journal:  Am J Physiol       Date:  1996-10

7.  Pharmacokinetic-pharmacodynamic modeling of caffeine: tolerance to pressor effects.

Authors:  J Shi; N L Benowitz; C P Denaro; L B Sheiner
Journal:  Clin Pharmacol Ther       Date:  1993-01       Impact factor: 6.875

8.  Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis.

Authors:  Y Hashimoto; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1991-06
  8 in total
  139 in total

1.  Modelling of pain intensity and informative dropout in a dental pain model after naproxcinod, naproxen and placebo administration.

Authors:  Marcus A Björnsson; Ulrika S H Simonsson
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

2.  Simultaneous vs. sequential analysis for population PK/PD data II: robustness of methods.

Authors:  Liping Zhang; Stuart L Beal; Lewis B Sheinerz
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-12       Impact factor: 2.745

3.  Evaluation of IPPSE, an alternative method for sequential population PKPD analysis.

Authors:  B D Lacroix; L E Friberg; M O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-01-21       Impact factor: 2.745

4.  Population pharmacokinetics and pharmacodynamics of bivalirudin in young healthy Chinese volunteers.

Authors:  Dong-mei Zhang; Kun Wang; Xia Zhao; Yun-fei Li; Qing-shan Zheng; Zi-ning Wang; Yi-min Cui
Journal:  Acta Pharmacol Sin       Date:  2012-06-04       Impact factor: 6.150

5.  Effect of CYP2C19 genotypes on the pharmacokinetic/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers.

Authors:  Yu-Cheng Sheng; Kun Wang; Ying-Chun He; Juan Yang; Qing-Shan Zheng
Journal:  Eur J Clin Pharmacol       Date:  2010-09-14       Impact factor: 2.953

6.  Pharmacodynamics-mediated drug disposition (PDMDD) and precursor pool lifespan model for single dose of romiplostim in healthy subjects.

Authors:  Yow-Ming C Wang; Wojciech Krzyzanski; Sameer Doshi; Jim J Xiao; Juan Jose Pérez-Ruixo; Andrew T Chow
Journal:  AAPS J       Date:  2010-10-21       Impact factor: 4.009

7.  Implementation and evaluation of the SAEM algorithm for longitudinal ordered categorical data with an illustration in pharmacokinetics-pharmacodynamics.

Authors:  Radojka M Savic; France Mentré; Marc Lavielle
Journal:  AAPS J       Date:  2010-11-11       Impact factor: 4.009

8.  Prediction of repeat-dose occupancy from single-dose data: characterisation of the relationship between plasma pharmacokinetics and brain target occupancy.

Authors:  Sergio Abanades; Jasper van der Aart; Julien A R Barletta; Carmine Marzano; Graham E Searle; Cristian A Salinas; Javaad J Ahmad; Richard R Reiley; Sabina Pampols-Maso; Stefano Zamuner; Vincent J Cunningham; Eugenii A Rabiner; Marc A Laruelle; Roger N Gunn
Journal:  J Cereb Blood Flow Metab       Date:  2010-10-13       Impact factor: 6.200

9.  Predicting allopurinol response in patients with gout.

Authors:  Daniel F B Wright; Stephen B Duffull; Tony R Merriman; Nicola Dalbeth; Murray L Barclay; Lisa K Stamp
Journal:  Br J Clin Pharmacol       Date:  2015-12-29       Impact factor: 4.335

10.  A comprehensive evaluation of exposure-response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis.

Authors:  Chuanpu Hu; Zhenling Yao; Yang Chen; Bruce Randazzo; Liping Zhang; Zhenhua Xu; Amarnath Sharma; Honghui Zhou
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-03-16       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.